Corporate News Update: Market Performance and Strategic Context of Oncopeptides
Oncopeptides AB (ticker ONCO.ST) experienced a modest decline of 0.58 % during a 24‑hour trading window that closed at 04:09 AM Central Europe on Thursday, 22 nd. At the close, the share price settled at approximately SEK 1.69 on the Stockholm Stock Exchange. The company’s outstanding share base stands at 393.7 million shares, translating into a current market capitalisation of SEK 672 million. Over the last 24 hours, the aggregate trading volume amounted to roughly SEK 6.1 million.
Recent Performance Overview
- Year‑over‑Year: Since the close of the previous month, the share price has fallen 18.18 %.
- Moving Average: The 200‑day simple moving average sits at SEK 1.94, indicating a relatively weak trend over the medium term.
- 52‑Week Range: The stock’s highest price over the past year was SEK 6.14 on 11 March 2025, while its lowest price was SEK 1.26 on 5 December 2026, highlighting substantial volatility in a short period.
Comparative Peer Activity
During the same 24‑hour window, several peer companies in the Swedish biotech and pharmaceutical landscape recorded the following price movements:
| Company | Ticker | % Change | Current Price (SEK) | Market Capitalisation (SEK mn) | P/E Ratio |
|---|---|---|---|---|---|
| Aac Clyde Space | AAC.ST | –2.64 % | 98.9 | 754.7 | – |
| Embellence | EMBELL.ST | –0.32 % | 31.1 | 746.2 | 12.98 |
| Novotek –B | NTEK‑B.ST | –2.70 % | 68.5 | 730.3 | 49.83 |
| Mangold | MANG.ST | –0.62 % | 1 580 | 761.9 | 50.82 |
| Dicot Pharma | DICOT.ST | +2.96 % | 0.21 | 727.7 | – |
The broader sector exhibits a mixed picture, with some peers gaining modestly (e.g., Dicot Pharma) while others decline, reflecting varying investor sentiment toward different therapeutic areas and business models.
Company Profile
Oncopeptides AB is a Stockholm‑based biotechnology firm that specialises in the development of cancer therapies. Its proprietary platform focuses on generating pro‑drugs that enhance the efficacy of cytotoxic agents, offering a potential therapeutic advantage over conventional chemotherapy. The company is publicly listed on the Swedish Stock Exchange and maintains a presence in the broader European pharmaceutical market.
For further information on Oncopeptides’ pipeline and corporate strategy, visit the company’s official website at www.oncopeptides.se .